{"id":52739,"date":"2023-01-10T12:02:12","date_gmt":"2023-01-10T11:02:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/"},"modified":"2023-01-10T12:02:12","modified_gmt":"2023-01-10T11:02:12","slug":"vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/","title":{"rendered":"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma\u2019s CMC (chemistry, manufacturing and controls) development<\/i>\n<\/li>\n<li>\n<i>Project to accelerate the technical development of Vector BioPharma\u2019s gene delivery platform<\/i>\n<\/li>\n<li>\n<i>Announcement follows Vector BioPharma\u2019s $30 million Series A fundraising in August 2022<\/i>\n<\/li>\n<\/ul>\n<p>BASEL, Switzerland&#8211;(BUSINESS WIRE)&#8211;Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that it has entered into a strategic, multi-phase collaboration with the Instituto de Biologia Experimental e Tecnol\u00f3gica (iBET), a world-leading research-intensive organization specialized in biotechnology research and bioprocess development. The partnership aims to develop high-throughput quantification methods to advance the technical development of Vector\u2019s gene delivery platform.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230110005585\/en\/1681726\/5\/logo-tagline.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230110005585\/en\/1681726\/21\/logo-tagline.jpg\"><\/a><\/p>\n<p>\nVector BioPharma\u2019s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins. Utilizing iBET\u2019s expertise in developing integrated bioprocesses and analytical methods for the production, purification and characterization of virus-based pharmaceuticals, the collaboration will be executed in multiple stages. Initially, the collaboration will seek to develop a high-throughput analytical method for full-to-empty capsid ratio quantification from both in-process and final purified samples. Monitoring the full-to-empty capsid ratio, which is a critical quality attribute of virus-based biotherapeutics, is used to determine the purity and safety of such products during the manufacturing process and at the final product stage. Subsequent collaboration stages will focus on the upstream process development for the large-scale manufacturing of Vector BioPharma\u2019s virus-like particles.\n<\/p>\n<p>\n<b>Lorenz Mayr, Ph.D., CEO at Vector BioPharma, said:<\/b> <i>\u201cCollaboration with industry-leading R&amp;D institutions and researchers in the biopharmaceutical manufacturing sector is key to accelerating the development of Vector BioPharma\u2019s proprietary gene delivery platform as we look towards large scale and GMP manufacturing. Considering iBET\u2019s track record of prestigious RD&amp;I technology transfer projects with companies across the globe, we are confident in this project to rapidly accelerate the development of our gene delivery platform.\u201d<\/i>\n<\/p>\n<p>\n<b>Micha H\u00e4uptle, Ph.D., Head of CMC at Vector BioPharma, said:<\/b> <i>\u201cWe are delighted to enter a collaboration with iBET, a world-class expert in the field of manufacturing process and analytical development for viral vectors. We look forward to leveraging iBET\u2019s experience in the virus-based biopharmaceutical sector, for the development of precise analytical methods and robust manufacturing processes for Vector BioPharma\u2019s virus-like particles designed for precise gene delivery.\u201d<\/i>\n<\/p>\n<p>\n<b>Paula Alves, Ph.D., CEO at iBET, said:<\/b> \u201c<i>iBET is thrilled to partner with such a creative team as Vector BioPharma which, like us, excels at applying cutting-edge technologies from academic research to create innovative viral vectors for gene delivery. Vector BioPharma\u2019s challenges to develop next-generation therapeutics for high-precision gene delivery will motivate our efforts to succeed.<\/i><i> This partnership is iBET\u00b4s most recent contribution to global health initiatives with its bioprocess development and bioanalytics know-how to bring safe and improved medicines to the clinic.\u201d<\/i>\n<\/p>\n<p>\n<b>Ant\u00f3nio Rold\u00e3o, Ph.D., Coordinator of Late-stage R&amp;D Bioproduction Unit at iBET, said:<\/b> \u201c<i>It is an honour that Vector Biopharma has appointed iBET to partner in the development of such an innovative and potentially transformative new modality. We are confident that the competences and expertise of iBET in bioprocess and analytics development for gene therapy applications will complement Vector BioPharma\u2019s know-how on viral particles engineering to potentiate its innovative gene delivery platform. Looking forward to a fruitful and exciting collaboration.\u201d<\/i>\n<\/p>\n<p>\nTo learn more about Vector BioPharma, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vectorbiopharma.com&amp;esheet=53189792&amp;newsitemid=20230110005585&amp;lan=en-US&amp;anchor=www.vectorbiopharma.com&amp;index=1&amp;md5=5d3905ab3dff2cbbdf2476aa121df5b4\" rel=\"nofollow noopener\" shape=\"rect\">www.vectorbiopharma.com<\/a><br \/>To learn more about iBET, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ibet.pt&amp;esheet=53189792&amp;newsitemid=20230110005585&amp;lan=en-US&amp;anchor=www.ibet.pt&amp;index=2&amp;md5=8f8b7ade12c472b3e00314b55fa20546\" rel=\"nofollow noopener\" shape=\"rect\">www.ibet.pt<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact:<\/b><br \/>Dr. Maria Spyrou<br \/>\n<br \/>E-mail: <a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x6d;a&#114;&#x69;a&#46;&#x73;&#112;&#x79;&#x72;&#111;&#x75;&#x40;&#122;&#x79;m&#101;&#x63;o&#109;&#x6d;u&#110;&#x69;c&#97;&#x74;&#105;&#x6f;&#x6e;&#115;&#x2e;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#x61;&#114;ia&#x2e;&#x73;&#112;&#121;r&#x6f;&#x75;&#64;&#122;y&#x6d;&#x65;&#x63;&#111;mm&#x75;&#x6e;&#105;&#99;a&#x74;&#x69;&#111;&#110;s&#x2e;&#x63;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma\u2019s CMC (chemistry, manufacturing and controls) development Project to accelerate the technical development of Vector BioPharma\u2019s gene delivery platform Announcement follows Vector BioPharma\u2019s $30 million Series A fundraising in August 2022 BASEL, Switzerland&#8211;(BUSINESS WIRE)&#8211;Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52739","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma\u2019s CMC (chemistry, manufacturing and controls) development Project to accelerate the technical development of Vector BioPharma\u2019s gene delivery platform Announcement follows Vector BioPharma\u2019s $30 million Series A fundraising in August 2022 BASEL, Switzerland&#8211;(BUSINESS WIRE)&#8211;Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-10T11:02:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230110005585\/en\/1681726\/21\/logo-tagline.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery\",\"datePublished\":\"2023-01-10T11:02:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/\"},\"wordCount\":615,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005585\\\/en\\\/1681726\\\/21\\\/logo-tagline.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/\",\"name\":\"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005585\\\/en\\\/1681726\\\/21\\\/logo-tagline.jpg\",\"datePublished\":\"2023-01-10T11:02:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005585\\\/en\\\/1681726\\\/21\\\/logo-tagline.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230110005585\\\/en\\\/1681726\\\/21\\\/logo-tagline.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/","og_locale":"en_US","og_type":"article","og_title":"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery - Pharma Trend","og_description":"Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma\u2019s CMC (chemistry, manufacturing and controls) development Project to accelerate the technical development of Vector BioPharma\u2019s gene delivery platform Announcement follows Vector BioPharma\u2019s $30 million Series A fundraising in August 2022 BASEL, Switzerland&#8211;(BUSINESS WIRE)&#8211;Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-10T11:02:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230110005585\/en\/1681726\/21\/logo-tagline.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery","datePublished":"2023-01-10T11:02:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/"},"wordCount":615,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230110005585\/en\/1681726\/21\/logo-tagline.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/","url":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/","name":"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230110005585\/en\/1681726\/21\/logo-tagline.jpg","datePublished":"2023-01-10T11:02:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230110005585\/en\/1681726\/21\/logo-tagline.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230110005585\/en\/1681726\/21\/logo-tagline.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vector-biopharma-and-ibet-collaborate-to-develop-high-throughput-analytical-methods-and-scalable-processes-for-gene-delivery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Vector BioPharma and iBET Collaborate to Develop High-Throughput Analytical Methods and Scalable Processes for Gene Delivery"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52739"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52739\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}